

Special Issue

Human T-Cell Leukemia Virus (HTLV) Infection and Treatment: 2nd Edition

Message from the Guest Editors

We invite you to contribute original research or review to this Special Issue of *Viruses* that will highlight advances in HTLV-1 research.

The first human retrovirus human T-cell leukemia virus type 1 (HTLV-1) was identified in 1980. As a retrovirus, HTLV-1 integrates into the host genome and causes a persistent lifelong infection. HTLV-1 causes an aggressive fatal malignancy known as adult T-cell leukemia/lymphoma (ATLL), the neurodegenerative disease HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-1 associated uveitis, infectious dermatitis and inflammatory conditions. In addition, HTLV-1 infection is associated with a higher mortality and morbidity.

Despite being investigated for over 40 years, many fundamental questions in HTLV-1 pathogenesis remain unresolved. In this Special Issue, we will focus on the most recent advances in understanding the mechanism of HTLV infection, with an emphasis on treatment and diagnosis. We will also focus on new developments in biomarkers, prevention, animal models and disease pathogenesis.

Guest Editors

Dr. Cynthia A. Pise-Masison

Animal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Dr. Damian F. J. Purcell

1. Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
2. Global Virus Network Center of Excellence, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia

Deadline for manuscript submissions



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/245507

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).